Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Rachel Tate uptoTate
3 years 1 month ago
PJP occurs in pts w/ AAV who undergo treatment w/ CYC or RTX, but PJP PPX assoc'd w/ inc incidence of medication-related adverse events. Abs 1081 #ACR22 @RheumNow https://t.co/7vMgx7eMAP https://t.co/bhKPtJBMAO
Dr. Rachel Tate uptoTate
3 years 1 month ago
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg
Julian Segan JulianSegan
3 years 1 month ago
From my colleague @aili_yoyo. Mimics of vasculitis picked up on imaging. "Isolated abdominal vasculitis" is a surprisingly common consult. Can be tricky sometimes.
@RheumNow #ACR22 #mimics https://t.co/QfeaTHHzdA
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Rheumatic Masqueraders: Mimics of Rheumatic Diseases
Mimics of Vasculitis by
- Demographics
- Vascular Distribution
-**Imaging
- Labs
- Clinical Presentation
#ACR22 @RheumNow https://t.co/o0pZoiMqI2
Julian Segan JulianSegan
3 years 1 month ago
FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression.
@RheumNow ABST1393 #ACR22
https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj
Richard Conway RichardPAConway
3 years 1 month ago
Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI
Dr. Rachel Tate uptoTate
3 years 1 month ago
Fascinating Abs 0653 #ACR22 In vitro models show JAKis counteract celluar cytotoxicity of HCQ in a human retinal pigment epithelial cell line and podocytes. Possible new way to dec. retinopathy/nephropathy? @RheumNow
https://t.co/5NtLoDzjKG https://t.co/GG2R03xAes
Dr. Rachel Tate uptoTate
3 years 1 month ago
BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV
Catherine Sims, MD DrCassySims
3 years 1 month ago
What delays diagnosis of AS? #ACR22 @RheumNow
Abstract #0328
Diagnosed faster if:
👨🦳Older age at back pain onset
🧬HLA-B27+
✋🦶peripheral arthritis
📍Higher socioeconomic vulnerability had diagnostic delay
👁 uveitis more common in patients with > 4 years dx delay
Dr. Rachel Tate uptoTate
3 years 1 month ago
Inverse association between average yearly HCQ dose and CV damage in cohort of SLE pts from Abs 0982 #ACR22 @RheumNow https://t.co/sfB6ONgwOa https://t.co/FAUGAVe2mB
Richard Conway RichardPAConway
3 years 1 month ago
Curtis et al @RADoctor . IL6i more effective than conventional immunomodulators in refractory PMR. More likely to discontinue GC (HR 1.32), minimal GC (<2mg) (HR 1.30). @RheumNow #ACR22 Abstr#1547 https://t.co/uzSzrLQ9cB https://t.co/G4pEkOgYm2
Richard Conway RichardPAConway
3 years 1 month ago
Alle et al. ITP develops into SLE 5.6/1000py. 5.4% of ITP in this study developed SLE after 1801.4py follow up. Assoc refractory ITP, low complement, cytopenias, LA, hypergamma, high titre ANA. @RheumNow #ACR22 Abstr#1455 https://t.co/ORTeB0Q9Pi https://t.co/AVo97uMbpW
David Liew drdavidliew
3 years 1 month ago
Nice RS3PE irAE description from CanRIO
Two of my RS3PE irAE pts: both severe Sx
one in 2018: not enough PNL until palliation & suffered until then
one in 2022: prompt diagnosis, right PNL dose, living v well now
Hopefully we always continue to improve
ASBT0758 #ACR22 @RheumNow https://t.co/5Ps2HRllNC
sheila RHEUMarampa
3 years 1 month ago
A diagnostic delay of 6 months of #psoriaticarthritis was assoc w/
⬆️incidence of depression
⬆️limitation in participation of social roles & activities
⬆️impact on QoL
in this study by George Gondo @NPF & team
🔖Take home msg: Early dx of PsA is key!
#ACR22 @RheumNow ABST1507 https://t.co/wIZT4MKV4b
Poster Hall